Acrivon Q1 net loss $16.5M; ACR-368 Phase 2b 50% ORR; $130M PIPE

Acrivon Therapeutics, Inc.

2024-Q1 EPS reported -$0.73

Net loss $16.5M vs $12.8M YoY; R&D $11.5M, G&A $6.2M.
ACR-368 Phase 2b: 50% confirmed ORR in OncoSignature-positive patients (10) vs 0% in negative (16), p=0.0038.
Endometrial cancer identified as new AP3-predicted sensitive tumor type; median DoR not yet reached.
ACR-2316 IND expected Q3 2024; Phase 1 start Q4 2024.
Closed oversubscribed $130M private placement at premium; cash ~$240M pro forma into H2 2026.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 1.0

Acrivon Therapeutics, Inc. reported first quarter ended March 31, 2024 results: net income $16.5 million.

Period: first quarter ended March 31, 2024
Net income: $16.5 million
Result: reported results

Exact text from the filing

Net loss for the quarter ended March 31, 2024 was $16.5 million compared to a net loss of $12.8 million for the same period in 2023.

View on SEC.gov

1341 earnings releases filed in the last 30 days. Browse all earnings releases →

Acrivon Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-24-059097

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.